Claims for Patent: 10,125,373

Summary for Patent: 10,125,373

Title:	Geminiviral vector for expression of rituximab
Abstract:	A single vector or multiple separate vectors that contain two or more non-competing replicons for transient expression of the heavy and light chains of Rituximab in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures to optimize the expression is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of the multi-replicon single vector system for producing Rituximab in plant cells.
Inventor(s):	Mason; Hugh (Phoenix, AZ), Arntzen; Charles (Gold Canyon, AZ), Rosenthal; Sun Hee (Santa Ana, CA), Winkle; Sean (Mesa, AZ), Diamos; Andrew (Tempe, AZ)
Assignee:	Arizona Board of Regents on Behalf of Arizona State University (Tempe, AZ)
Application Number:	14/762,128
Patent Claims:	1. A vector comprising a long intergenic region (LIR) of a geminivirus genome, followed by two nucleic acid segments followed by a short intergenic region (SIR) of a geminivirus genome, followed by one or more nucleic acids encoding Rep and RepA proteins of a geminivirus genome, followed by a LIR, wherein the two nucleic acid segments comprise: (a) a nucleic acid segment comprising at least one promoter, a 5'UTR, a region encoding a heavy chain of Ritixumab, and a 3' terminator; and (b) a nucleic acid segment comprising at least one promoter, a 5'UTR, a region encoding a light chain of Ritixumab, and a 3' terminator; wherein the two nucleic acid segments comprise a single replicon. 2. The vector of claim 1, further comprising a nucleic acid segment that comprises a gene-silencing inhibitor. 3. The vector of claim 1, wherein the 5'UTR of the first and second nucleic acid segment comprise the same sequence and the 3' terminator of the first and second nucleic acid segment comprise the same sequence. 4. The vector of claim 1, wherein the 5'UTR of the first and second nucleic acid segment do not comprise the same sequence and the 3' terminator of the first and second nucleic acid segment do not comprise the same sequence. 5. A method of producing Rituximab in a plant cell comprising: (a) obtaining a vector of claim 1 (b) introducing the vector into a plant cell; and (c) allowing expression of the replicon comprising the first and the second chain of Rituximab. 6. The method of claim 5, further comprising a full assembly of the first and the second chains of Rituximab. 7. The vector of claim 1, wherein the 3' terminator comprises a tobacco extensin gene terminator region.

Details for Patent 10,125,373

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2033-01-22
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2033-01-22